Search results
Showing 8686 to 8700 of 8947 results
First-ever NHS treatment approved for advanced Hodgkin lymphoma
New combination therapy offers hope to 800 people annually with late-stage blood cancer.
HST routing criteria: encouraging innovation in the treatment of ultra-rare diseases
Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging innovation in the treatment of ultra-rare diseases. He also highlights why effective routing is essential to getting the best care to patients across the NHS.
Changes approved to the routing criteria for highly specialised technologies
At its meeting on 19 March our Board approved changes to the criteria we use to decide which treatments should be evaluated, to ensure more consistent, predictable and transparent decisions.
Annual BMI checks recommended for adults with long-term conditions
We've published a draft quality standard calling for yearly BMI and waist-to-height measurements to help prevent weight-related complications.
First licensed treatment for ultra-rare immune disorder recommended
Leniolisib is the first ever treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) licensed for use in the NHS in England.
Today we've recommended the first long-term daily pill to treat endometriosis that could transform how this painful condition is managed.
Second consultation launched on NHS funding for Alzheimer's treatments
Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab.
NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in people aged 2 and over with severe haemophilia A.
New option for adult leukaemia patients as we recommend treatment
Today we've recommended an immunotherapy treatment that could prevent blood cancer from returning in adults who've responded well to initial therapy.
NICE describes how weight loss drug tirzepatide will be rolled out
The medication will initially be offered only to those people with the highest clinical needs.
An insight into one of NICE’s most long-standing collaborative relationships.
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018.
NICE recommends Enhertu for more people with advanced breast cancer
Hundreds more people eligible for breast cancer drug Enhertu as NICE recommends it for earlier stage disease, in final draft guidance.
NICE chronic lung disease treatment decision could benefit 5,200 people
NICE broadens nintedanib recommendation on chronic lung disease treatment.
Improvements for people with acute kidney injury in updated quality standard
An updated quality standard published today (23 March 2023) by NICE outlines improvements in care for people who have or are at risk of acute kidney injury.